$ESRX Express Scripts (ESRX) Overall Average: 96% Buy. Wednesday,

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Understanding the Sale of Guaranty Bancshares, Inc. The recent announcement regarding the proposed sale of Guaranty Bancshares, Inc. to Glacier Bancorp, Inc. has garnered significant attention. Shareholders will reportedly receive 1.0000 share of Glacier stock for each share they hold in Guaranty. This transaction raises important questions regarding its valuation and the...

Ascenz Marorka Enhances Fleet Performance Monitoring in the Americas Ascenz Marorka, the smart shipping arm of GTT, has recently made strides by expanding its Real-Time Fleet Performance Monitoring Service to encompass the Americas. This strategic development follows the success of deployments in renowned maritime hubs, showcasing Ascenz Marorka's commitment to enhancing...

Ares Management Expands Renewable Energy Footprint Recently, Ares Management Corporation (NYSE: ARES) announced a remarkable acquisition that underscores their commitment to renewable energy. A fund managed under the Ares Infrastructure Opportunities strategy has secured a 49% stake in a diverse energy asset portfolio valued at approximately $2.9 billion. This strategic...

RLX Technology to Announce Third Quarter Financial Results Internationally recognized for its innovative approach, RLX Technology Inc. (NYSE: RLX) is gearing up to unveil its financial performance for the third quarter, which will end September 30, 2025. This announcement will occur just before the U.S. markets open on November 14, 2025. As a global leader in the e-vapor...

Grok AI Federal Approval Marks a New Era The approval for Elon Musk's AI chatbot, Grok, to be utilized by all federal agencies represents a groundbreaking development in how artificial intelligence can enhance government operations. The General Services Administration (GSA) has granted this approval along with special provisions from Musk's AI company, xAI. Understanding...